Roles
- Professor
-
Biography
Richard A. Preston, M.D., MSPH, MBA, is Professor of Medicine, Chief of the Division of Clinical Pharmacology, Principal Investigator and Medical Director of the Clinical Pharmacology Phase I Research Unit at the Miller School of Medicine, University of Miami. Dr. Preston received his medical degree from the University of California, San Diego and completed his residency and nephrology fellowship at the University of Miami. Additionally, he has received a Master of Business Administration and a Master of Science in Public Health, both from the University of Miami.
Dr. Preston is board certified in Internal Medicine, Nephrology, and Clinical Pharmacology. He has conducted more than 400 clinical research investigations as principal investigator including more than 150 studies of pharmacokinetics/safety in patients with renal impairment and more than 150 studies of pharmacokinetics /safety in patients with hepatic impairment.
He has also conducted original pathophysiological investigations of mechanisms of hyperkalemia following dual renin-angiotensin-aldosterone blockade in chronic kidney disease, evidence supporting the existence of a novel gastrointestinal-renal kaliuretic signaling axis in humans, characterization of potassium-induced natriuresis in postmenopausal hypertensive women, and mechanisms of sodium sensitivity in metabolic syndrome. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Study Explores Potassium’s Protective Effect on Salt Excretion in Post-Menopausal, Hypertensive Hispanic Women
Translational Study Provides Clues to Potassium’s Beneficial Effect on Hypertension
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 12 clinical trials.
-
This is a research study in people with kidney disease and normal kidney function.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
A Phase 1 Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment Compared With Healthy Subjects
- Principal Investigator: Richard Preston
- Study Phase: Phase 1
- Enrollment Status: Closed
-
This is a research study in healthy subjects and subjects with kidney disease.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
This is a Phase 1, open-label, non-randomized, parallel-group study to evaluate the PK, safety, and tolerability of a single SC dose of 5 mg VK2735 in participants with varying degrees of hepatic function. The study will be conducted at approximately 2 Clinical Research Units (CRU) in the United States. The study includes a control group of healthy participants (Group 1) with normal hepatic function that will be demographically mean matched (sex, body mass index 15%, and age 10 years) to participants with mild, moderate, and severe hepatic impairment (Group 2, 3, or 4, respectively). A control participant may be matched to more than one hepatic impaired participant.
- Principal Investigator: Richard Preston
- Study Phase: TBD
- Enrollment Status: Open
-
This is a research study in people with liver disease and normal liver function.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
This is a research study in people with liver disease and normal liver function.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
This is a research study in people with liver disease and normal liver function.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
Phase 1 study to assess the safety and tolerability of lanifibranor in patients with mild, moderate or severe hepatic impairment (HI), as well as to characterize the PK parameters of lanifibranor and its metabolites in HI subjects and healthy volunteer
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
Potential participants searching UM's clinical research website will be provided this description and a link to the full details of your study.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (CC 90007) in Subjects With Mild, Moderate and Severe Hepatic Impairment
- Principal Investigator: Richard Preston
- Study Phase: Phase 1
- Enrollment Status: Closed
-
This is a research study in people with and without liver disease.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed
-
This is a research study in people with liver disease and healthy subjects with normal liver function.
- Principal Investigator: Richard Preston
- Study Phase: Phase I
- Enrollment Status: Closed